FibroGen Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h02 HE
|
FibroGen, Inc
Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...